anti-CD16A/anti-BCMA bispecific NK-cell engager (Affimed)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-CD16A/anti-BCMA bispecific NK-cell engager (Affimed)

Drug Alias Nameanti-CD16A/anti-BCMA bispecific immune-cell engager (Affimed)AFM-26+ (Affimed)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionImmunostimulantsNatural killer cells stimulantsTumor necrosis factor ligand superfamily member 13 modulators +[5]

TargetsLow affinity immunoglobulin gamma Fc region receptor IIITumor necrosis factor ligand superfamily member 13

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAffimed Nv

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAffimed Nv

Active IndicationsN/A

Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A